Jens Jakob Thune

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4129614/publications.pdf

Version: 2024-02-01

758635 580395 29 623 12 25 h-index citations g-index papers 29 29 29 1144 docs citations times ranked citing authors all docs

#	Article	IF	CITATIONS
1	Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failure. Circulation, 2017, 136, 1772-1780.	1.6	134
2	Simple Risk Stratification at Admission to Identify Patients With Reduced Mortality From Primary Angioplasty. Circulation, 2005, 112, 2017-2021.	1.6	118
3	Regional cardiac dysfunction and outcome in patients with left ventricular dysfunction, heart failure, or both after myocardial infarction. European Heart Journal, 2016, 37, 466-472.	1.0	40
4	Progression of cardiac involvement in patients with limb-girdle type 2 and Becker muscular dystrophies: A 9-year follow-up study. International Journal of Cardiology, 2015, 182, 403-411.	0.8	36
5	Distinction of salvaged and infarcted myocardium within the ischaemic area-at-risk with T2 mapping. European Heart Journal Cardiovascular Imaging, 2014, 15, 1048-1053.	0.5	35
6	Myocardial fibrosis and the effect of primary prophylactic defibrillator implantation in patients with non-ischemic systolic heart failureâ€"DANISH-MRI. American Heart Journal, 2020, 221, 165-176.	1.2	35
7	Mechanisms for overestimating acute myocardial infarct size with gadolinium-enhanced cardiovascular magnetic resonance imaging in humans: a quantitative and kinetic study. European Heart Journal Cardiovascular Imaging, 2015, 17, jev123.	0.5	30
8	Rationale, design, and baseline characteristics of the DANish randomized, controlled, multicenter study to assess the efficacy of Implantable cardioverter defibrillators in patients with non-ischemic Systolic Heart failure on mortality (DANISH). American Heart Journal, 2016, 179, 136-141.	1,2	29
9	Risk Models for Prediction of Implantable Cardioverter-Defibrillator Benefit. JACC: Heart Failure, 2019, 7, 717-724.	1.9	29
10	Long-Term Follow-Up of DANISH (The Danish Study to Assess the Efficacy of ICDs in Patients With) Tj ETQq0 0 C) rgBT /Ove	erlock 10 Tf 50
11	Early Gadolinium Enhancement for Determination of Area at Risk. JACC: Cardiovascular Imaging, 2017, 10, 130-139.	2.3	17
12	Rubidium-82 positron emission tomography for detection of acute doxorubicin-induced cardiac effects in lymphoma patients. Journal of Nuclear Cardiology, 2020, 27, 1698-1707.	1.4	15
13	¹²³ lâ€ <scp>MIBG</scp> imaging for detection of anthracyclineâ€induced cardiomyopathy. Clinical Physiology and Functional Imaging, 2018, 38, 176-185.	0.5	12
14	Prevalence and prognostic association of ventricular arrhythmia in non-ischaemic heart failure patients: results from the DANISH trial. Europace, 2021, 23, 587-595.	0.7	10
15	The effect of implantable cardioverter-defibrillator in patients with diabetes and non-ischaemic systolic heart failure. Europace, 2019, 21, 1203-1210.	0.7	9
16	Different prognostic impact of systolic function in patients with heart failure and/or acute myocardial infarction. European Journal of Heart Failure, 2005, 7, 852-858.	2.9	6
17	Cardiac magnetic resonance imaging after ventricular tachyarrhythmias increases diagnostic precision and reduces the need for family screening for inherited cardiac disease. Europace, 2016, 18, euv446.	0.7	6
18	Myocardial perfusion during atrial fibrillation in patients with non-ischaemic systolic heart failure: a cross-sectional study using Rubidium-82 positron emission tomography/computed tomography. European Heart Journal Cardiovascular Imaging, 2019, 20, 233-240.	0.5	6

#	Article	IF	CITATIONS
19	123I-MIBG for detection of subacute doxorubicin-induced cardiotoxicity in patients with malignant lymphoma. Journal of Nuclear Cardiology, 2020, 27, 931-939.	1.4	5
20	Periodic Repolarization Dynamics Identifies ICD Responders in Nonischemic Cardiomyopathy: A DANISH Substudy. Circulation, 2022, 145, 754-764.	1.6	5
21	Late potentials and their correlation with ventricular structure in patients with ventricular arrhythmias. PACE - Pacing and Clinical Electrophysiology, 2017, 40, 1466-1471.	0.5	4
22	NT-proBNP and ICD in Nonischemic Systolic HeartÂFailure. JACC: Heart Failure, 2022, 10, 161-171.	1.9	4
23	Defibrillators work: now it is time to find out who needs them. European Heart Journal, 2017, 38, 1747-1748.	1.0	3
24	Duration of Heart Failure and Effect of Defibrillator Implantation in Patients With Nonischemic Systolic Heart Failure. Circulation: Heart Failure, 2019, 12, e006022.	1.6	2
25	Impaired myocardial perfusion is associated with increasing end-systolic- and end-diastolic volumes in patients with non-ischemic systolic heart failure: a cross-sectional study using Rubidium-82 PET/CT. BMC Cardiovascular Disorders, 2019, 19, 68.	0.7	2
26	Atrial fibrillation is a marker of increased mortality risk in nonischemic heart failureâ€"Results from the DANISH trial. American Heart Journal, 2021, 232, 61-70.	1.2	2
27	Myocardial perfusion in patients with non-ischaemic systolic heart failure and type 2 diabetes: a cross-sectional study using Rubidium-82 PET/CT. International Journal of Cardiovascular Imaging, 2018, 34, 993-1001.	0.7	1
28	Cardiac magnetic resonance imaging provides more than a diagnosis. Europace, 2017, 19, euw253.	0.7	0
29	Response by Elming et al to Letter Regarding Article, "Age and Outcomes of Primary Prevention Implantable Cardioverter-Defibrillators in Patients With Nonischemic Systolic Heart Failureâ€. Circulation, 2018, 137, 2190-2190.	1.6	0